Učitavanje...
Re-purposing cancer therapeutics for breast cancer immunotherapy
After decades of work to develop immune-based therapies for cancer, the first drugs designed specifically to engage the host anti-tumor immune response for therapeutic benefit were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer-Verlag
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3582212/ https://ncbi.nlm.nih.gov/pubmed/22454154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1247-z |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|